MARKET

IOVA

IOVA

Iovance Biotherp
NASDAQ
9.58
+0.05
+0.52%
After Hours: 9.50 -0.08 -0.84% 17:21 09/30 EDT
OPEN
9.46
PREV CLOSE
9.53
HIGH
10.09
LOW
9.46
VOLUME
1.76M
TURNOVER
0
52 WEEK HIGH
27.96
52 WEEK LOW
6.18
MARKET CAP
1.51B
P/E (TTM)
-3.9893
1D
5D
1M
3M
1Y
5Y
CRSR, INSG and IOVA are among after hour movers
Gainers: Relmada Therapeutics (RLMD) +10%. Rent t...
Seekingalpha · 09/23 21:31
BRIEF-Iovance Biotherapeutics Says Court Entered Scheduling Order
BRIEF-Iovance Biotherapeutics Says Court Entered Scheduling Order
Reuters · 09/12 22:06
Iovance Biotherapeutics to Present at Upcoming Conferences
SAN CARLOS, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present at the fol...
GlobeNewswire · 09/06 20:01
Iovance Biotherapeutics to Present Posters at ESMO 2022
SAN CARLOS, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced the publication of abstracts reporting clinical da...
GlobeNewswire · 09/06 13:00
AMRS, IOVA and AVDL are among after hour movers
Gainers: Vaccitech (VACC) +5%. Iovance Biotherapeutics (<a hre...
Seekingalpha · 08/26 21:27
5 Top Stocks Cathie Wood Is Selling This Week
Investor Place · 08/26 20:53
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
Benzinga · 08/25 22:43
Biomedical technician training program launches to support Philadelphia's growing life sciences sector
The program is focused on connecting people from disadvantaged communities with jobs that don't require a college degree.
American City Business Journals · 08/25 17:05
More
About IOVA
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cell therapies as cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. It has developed a new, shorter manufacturing process for tumor infiltrating lymphocyte (TIL) known as Generation 2 (Gen 2), which yields a cryopreserved TIL product. Its lead product candidates include lifileucel for metastatic melanoma and metastatic cervical cancer, as well as LN-145 for metastatic non-small cell lung cancer (NSCLC). In addition, the Company is investigating the combinations of TIL therapy with immune checkpoint inhibitors (ICIs) in metastatic melanoma, cervical cancer (NSCLC), and head and neck squamous cell carcinoma (HNSCC). It is investigating peripheral blood lymphocyte (PBL) therapy for patients with refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Webull offers kinds of Iovance Biotherapeutics Inc stock information, including NASDAQ:IOVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IOVA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IOVA stock methods without spending real money on the virtual paper trading platform.